Complementary treatment of siTERT for improving the antitumor effect of TERT-specific I-131 therapy

Cancer Gene Therapy

Volumn 19, Issue 4, 2012, Pages 263-270

  Kim, S ^a,b   Youn, H ^a,c   Song, M G ^a,b   Kang, J H ^d   Chung, H K ^a,b   Lee, D S ^a,e   Chung, J K ^a,b,f  

^a Seoul National University College of Medicine   (South Korea)

^b Seoul National University   (South Korea)

^c Seoul National University Cancer Hospital   (South Korea)

^d Korea Institute of Radiation and Medical Science   (South Korea)

^e Seoul National University   (South Korea)

^f Seoul National University Hospital   (South Korea)

Author keywords

complementary gene therapy; radioiodine therapy; siTERT; telomerase reverse transcriptase

Indexed keywords

3 (4,5 DIMETHYL 2 THIAZOLYL) 2,5 DIPHENYLTETRAZOLIUM BROMIDE; IODINE 131; LIPOCORTIN 5; MESSENGER RNA; RADIOISOTOPE; SHORT HAIRPIN RNA; SODIUM IODIDE SYMPORTER; TECHNETIUM 99M; TELOMERASE REVERSE TRANSCRIPTASE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CELL ASSAY; CELL POPULATION; CELL PROLIFERATION; CELL SURVIVAL; CELL VIABILITY; CLONOGENIC ASSAY; CONTROLLED STUDY; GENE THERAPY; HUMAN; HUMAN CELL; IN VIVO STUDY; MOUSE; NONHUMAN; PRIORITY JOURNAL; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SINGLE PHOTON EMISSION COMPUTER TOMOGRAPHY; STAINING; TELOMERIC REPEAT AMPLIFICATION PROTOCOL; TUMOR; TUMOR GROWTH; TUMOR MODEL; WESTERN BLOTTING;

ANIMALS; APOPTOSIS; CELL LINE; CELL PROLIFERATION; COMBINED MODALITY THERAPY; GENE EXPRESSION REGULATION, NEOPLASTIC; GENE ORDER; GENE SILENCING; GENETIC VECTORS; HUMANS; IODINE RADIOISOTOPES; MICE; MICE, NUDE; NEOPLASMS; RETROVIRIDAE; RNA INTERFERENCE; SYMPORTERS; TELOMERASE; XENOGRAFT MODEL ANTITUMOR ASSAYS;

MUS MUSCULUS;

EID: 84862799432     PISSN: 09291903     EISSN: 14765500     Source Type: Journal    
DOI: 10.1038/cgt.2011.88     Document Type: Article

References (22)

1. Lee YL, Lee YJ, Ahn SJ, Choi TH, Moon BS, Cheon GJ et al. Combined radionuclide-chemotherapy and in vivo imaging of hepatocellular carcinoma cells after transfection of a triple-gene construct, NIS, HSV1-sr39tk, and EGFP. Cancer Lett 2010; 290: 129-138.
2. Park SY, Kwak W, Thapa N, Jung MY, Nam JO, So IS et al. Combination therapy and noninvasive imaging with a dual therapeutic vector expressing MDR1 short hairpin RNA and a sodium iodide symporter. J Nucl Med 2003; 49: 1480-1488.
3. Shay JW, Keith WN. Targeting telomerase for cancer therapeutics. Br J Cancer 2008; 98: 677-683. (Pubitemid 351272604)
4. Tarkanyi I, Horváth A, Szatmari I, Eizert H, Vámosi G, Damjanovich S et al. Inhibition of human telomerase by oligonucleotide chimeras, composed of an antisense moiety and a chemically modified homo-oligonucleotide. FEBS Lett 2005; 6: 1411-1416. (Pubitemid 40289189)
5. Kurvinen K, Rantanen V, Syrjänen S, Johansson B. Radiation-induced effects on telomerase in gynecological cancer cell lines with different radiosensitivity and repair capacity. Int J Radiat Biol 2006; 82: 859-867. (Pubitemid 46009576)
6. Kim SH, Chung HK, Kang JH, Kim KI, Jeon YH, Jin YN et al. Tumor-targeted radionuclide imaging and therapy based on human sodium iodide symporter gene driven by a modified telomerase reverse transcriptase promoter. Hum Gene Ther 2008; 19: 951-957.
7. Takeshita F, Ochiya T. Therapeutic potential of RNA interference against cancer. Cancer Sci 2006; 97: 689-696. (Pubitemid 43983779)
8. Jia F, Zhang YZ, liu C. A retrovirus-based system to stably silence hepatitis B virus genes by RNA interference. Biotechnol Lett 2006; 28: 1679-1685. (Pubitemid 44369333)
9. Zhao P, Wang C, Fu Z, You Y, Cheng Y, Lu X et al. Lentiviral vector mediated siRNA knock-down of hTERT results in diminished capacity in invasiveness and in vivo growth of human glioma cells in a telomere length-independent manner. Int J Oncol 2007; 31: 361-368.
10. Pallini R, Sorrentino A, Pierconti F, Maggiano N, Faggi R, Montano N et al. Telomerase inhibition by stable RNA interference impairs tumor growth and angiogenesis in glioblastoma xenografts. Int J Cancer 2006; 118: 2158-2167.
11. Guo Y, Xie J, Rubin E, Tang YX, Lin F, Zi X et al. Frzb, a secreted Wnt antagonist, decreases growth and invasiveness of fibrosarcoma cells associated with inhibition of Met signaling. Cancer Res 2008; 68: 3350-3360.
12. Kim E, Kim JH, Shin HY, Lee H, Yang JM, Kim J et al. AdmTERT-delta19, a conditional replication-competent adenovirus driven by the human telomerase promoter, selectively replicates in and elicits cytopathic effect in a cancer cell-specific manner. Hum Gene Ther 2003; 14: 1415-1428. (Pubitemid 37268220)
13. Hahn WC. Telomerase and Cancer: Where and When? Clin Cancer Res 2001; 7: 2953-2954. (Pubitemid 32963810)
14. Ahn SJ, Jeon YH, Lee YJ, Lee YL, Lee SW, Ahn BC et al. Enhanced anti-tumor effects of combined MDR1 RNA interference and human sodium/iodide symporter (NIS) radioiodine gene therapy using an adenoviral system in a colon cancer model. Cancer Gene Ther 2010; 17: 492-500.
15. Poole JC, Andrews LG, Tollefsbol TO. Activity, function, and gene regulation of the catalytic subunit of telomerase (hTERT). Gene 2001; 269: 1-12. (Pubitemid 32488901)
16. Liao Z, Huang C, Zhou F, Xiong J, Bao J, Zhang H et al. Radiation enhances suicide gene therapy in radioresistant laryngeal squamous cell carcinoma via activation of a tumor-specific promoter. Cancer Lett 2009; 283: 20-28.
17. EI-Daly H, Kull M, Zimmermann S, Pantic M, Waller CF, Martens UM. Selective cytotoxicity and telomere damage in leukemia cells using the telomerase inhibitor BIBR1532. Blood 2005; 105: 1742-1749.
18. Gellert G, Dikmen Z, Wright W, Gryaznov S, Shay J. Effects of a novel telomerase inhibitor, GRN163L, in human breast cancer. Breast Cancer Res Treat 2006; 96: 73-81.
19. Saretzki G, Ludwig A, von Zglinicki T, Runnebaum IB. Ribozyme-mediated telomerase inhibition induces immediate cell loss but not telomere shortening in ovarian cancer cells. Cancer Gene Ther 2001; 8: 827-834. (Pubitemid 32983139)
20. Dong X, Liu A, Zer C, Feng J, Zhen Z, Yang M et al. siRNA inhibition of telomerase enhances the anti-cancer effect of doxorubicin in breast cancer cells. BMC Cancer 2009; 9: 133.
21. Zhang PH, Zou L, Tu ZG. RNAi-hTERT Inhibition hepatocellular carcinoma cell proliferation via decreasing telomerase activity. J Surg Res 2006; 131: 143-149. (Pubitemid 43227598)
22. Bauer G, Dao MA, Case SS, Meyerrose T, Wirthlin L, Zhou P et al. In vivo biosafety model to assess the risk of adverse events from retroviral and lentiviral vectors. Mol Ther 2008; 16: 1308-1315. (Pubitemid 351866063)